DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • August 6th, 2013 • Oncothyreon Inc. • Services-commercial physical & biological research • New York
This Development and Commercialization Agreement (the “Agreement”), entered into as of May 29, 2013 (the “Effective Date”), is made by and between Array BioPharma Inc., a Delaware corporation, having offices at 3200 Walnut Street, Boulder, Colorado 80301, and Oncothyreon Inc., a Delaware corporation, having offices at with offices at 2601 Fourth Ave., Suite 500, Seattle WA 98121.
Biomira Management Inc. Date April 30, 2013 Attn: Robert L. Kirkman, M.D. Division/Dept. LE-TA Trademarks Group A SEATTLE, WA 98004 Phone +49 6151 72-6020 USA Fax +49 6151 72-3378 E-Mail thomas.tresper@merckgroup.comOncothyreon Inc. • August 6th, 2013 • Services-commercial physical & biological research
In view of the above, MERCK proposes the following amendments (“Letter Amendment”) to the Amended and Restated License Agreement (2008) effective as of December 18, 2008, between Biomira Management Inc. (“ONCOTHYREON”) and MERCK (“Amended and Restated License Agreement”):
